Biogen in $1.25 billion deal with Forward Pharma to protect MS drug

(Reuters) - Biogen Inc said on Tuesday it would pay Forward Pharma A/S $1.25 billion in cash to gain access to the Danish company's intellectual property as it seeks to protect the patent life of its flagship multiple sclerosis drug, Tecfidera.